ELAVL1 promotes cell proliferation and migration of cells of the prostate cancer lines LNCaP and PC-3 by targeting vascular endothelial growth factors A and C and COX-2 (Barbisan et al., 2009; Mitsunari et al., 2016). Here, ELAVL1 is linked to prostate carcinoma.